BioSpace News Archive

Illuminate, Inc., the provider of software that unlocks vital unstructured clinical information lost in the EMR that can drive patient care improvements, announces the ability to identify more types of aneurysms.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in cell-free, enzymatic DNA production, today announced that it will report fiscal 2022 second quarter financial results after market close on Thursday, May 12, 2022.

The Diabetes Research Institute along with the Diabetes Research Institute Foundation Canada and Alberta Diabetes Institute at the University of Alberta, Canada’s largest stand-alone research facility dedicated to finding a cure of diabetes, announced the launch of a research partnership to advance efforts to find a cure for diabetes.

Longeveron Inc. announced the resignation of Chief Executive Officer Geoff Green, who is leaving the Company effective June 1st, 2022, to pursue new opportunities.

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced financial results for the three months ended March 31, 2022.

Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the first quarter of 2022 and provided an update on recent corporate highlights.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2022 financial results and business updates.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the first quarter ended March 31, 2022.

Emulate, Inc. today announced its new colon immune cell recruitment application, enabling the most human-relevant preclinical assessment of inflammatory bowel disease (IBD) drug candidates.